Literature DB >> 25895459

MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.

Rui Li1, Xuejun Shi2, Fengyu Ling1, Chunguang Wang1, Junxia Liu1, Wei Wang1, Ming Li1.   

Abstract

Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. The miR-34 family is directly transactivated by tumor suppressor p53 which is frequently mutated in various cancers; however, the effect of miR-34a on the ovarian cancer cells remains unclear. The aim of the paper was to study the expression of miR-34a in ovarian cancer and miR-34a's relation to the cell proliferation and metastasis in ovarian cancer in vitro. miR-34a expression was determined by quantitative RT-PCR in a panel of 60 human ovarian cancer samples. Functional characterization of miR-34a was accomplished by reconstitution of miR-34a expression in ovarian cancer cells by determining changes in proliferation, migration, and invasion. Our results showed that miR-34a is downregulated in ovarian cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of miR-34a was significantly lower in ovarian cancer cell lines in comparison with normal human fallopian tube epithelial cell line. The 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-diphenytetrazoliumromide (MTT) assay revealed significant cell proliferation inhibition in miR-34a transfectant compared with the control from HO8910 and SKOV3 cells, which displayed lowest expressions of miR-34a. Furthermore, the transwell assay also showed significant cell migration inhibition in miR-34a transfectant, compared with cell lines transfected with NC. Overexpression of miR-34a led to the inhibition of AXL expression, indicating that AXL is a target gene for miR-34a. Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer.

Entities:  

Keywords:  AXL; MiR-34a; Migration; Ovarian cancer; P53; Proliferation

Mesh:

Substances:

Year:  2015        PMID: 25895459     DOI: 10.1007/s13277-015-3445-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  21 in total

Review 1.  MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing.

Authors:  Victor Ambros
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

Review 2.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship.

Authors:  Amy E Pasquinelli
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

3.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

4.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.

Authors:  Xi Wang; Jinge Li; Ke Dong; Fang Lin; Min Long; Yongri Ouyang; Junxia Wei; Xi Chen; Yuanyuan Weng; Ting He; Huizhong Zhang
Journal:  Cell Signal       Date:  2014-12-10       Impact factor: 4.315

5.  MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.

Authors:  Mei-Yi Wu; Junjiang Fu; Xiuli Xiao; Jingbo Wu; Ray-Chang Wu
Journal:  Cancer Lett       Date:  2014-08-27       Impact factor: 8.679

6.  p53-mediated activation of miRNA34 candidate tumor-suppressor genes.

Authors:  Guido T Bommer; Isabelle Gerin; Ying Feng; Andrew J Kaczorowski; Rork Kuick; Robert E Love; Yali Zhai; Thomas J Giordano; Zhaohui S Qin; Bethany B Moore; Ormond A MacDougald; Kathleen R Cho; Eric R Fearon
Journal:  Curr Biol       Date:  2007-07-26       Impact factor: 10.834

7.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

8.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.

Authors:  Minoru Toyota; Hiromu Suzuki; Yasushi Sasaki; Reo Maruyama; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

9.  MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.

Authors:  Wei-Yu Chen; Shih-Yang Liu; Yung-Sheng Chang; Juan Juan Yin; Hsiu-Lien Yeh; Tarek H Mouhieddine; Ola Hadadeh; Wassim Abou-Kheir; Yen-Nien Liu
Journal:  Oncotarget       Date:  2015-01-01

10.  Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a.

Authors:  Xiangsheng Xiao; Bo Chen; Xiaoping Liu; Peng Liu; Guopei Zheng; Feng Ye; Hailin Tang; Xiaoming Xie
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

View more
  17 in total

Review 1.  Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwen Kollmorgen; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

Review 2.  MicroRNAs in gynecological cancers: Small molecules with big implications.

Authors:  Sanjeev K Srivastava; Aamir Ahmad; Haseeb Zubair; Orlandric Miree; Seema Singh; Rodney P Rocconi; Jennifer Scalici; Ajay P Singh
Journal:  Cancer Lett       Date:  2017-05-24       Impact factor: 8.679

3.  MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.

Authors:  Xiaoqin Liu; Guohong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  MicroRNA Exert Macro Effects on Cancer Bone Metastasis.

Authors:  Scott R Baier; Yihong Wan
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

5.  Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Authors:  Gabriel Schmid; Sara Notaro; Daniel Reimer; Samira Abdel-Azim; Michaela Duggan-Peer; Jessica Holly; Heidi Fiegl; Julia Rössler; Annemarie Wiedemair; Nicole Concin; Peter Altevogt; Christian Marth; Alain Gustave Zeimet
Journal:  BMC Cancer       Date:  2016-02-15       Impact factor: 4.430

Review 6.  The Receptor Tyrosine Kinase AXL in Cancer Progression.

Authors:  Erinn B Rankin; Amato J Giaccia
Journal:  Cancers (Basel)       Date:  2016-11-09       Impact factor: 6.639

7.  NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2.

Authors:  Nan Ding; Haiying Wu; Tao Tao; Erxuan Peng
Journal:  Onco Targets Ther       Date:  2017-10-06       Impact factor: 4.147

8.  Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.

Authors:  Fang-Hui Ren; Hong Yang; Rong-Quan He; Jing-Ning Lu; Xing-Gu Lin; Hai-Wei Liang; Yi-Wu Dang; Zhen-Bo Feng; Gang Chen; Dian-Zhong Luo
Journal:  BMC Cancer       Date:  2018-01-03       Impact factor: 4.430

9.  MicroRNA‑205 promotes the tumorigenesis of nasopharyngeal carcinoma through targeting tumor protein p53-inducible nuclear protein 1.

Authors:  Guohui Nie; Hongfang Duan; Xiaoqing Li; Zhendong Yu; Liang Luo; Ruijing Lu; Ziliang Ji; Wei Zhang
Journal:  Mol Med Rep       Date:  2015-08-05       Impact factor: 2.952

10.  Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.

Authors:  Pinar Kanlikilicer; Bulent Ozpolat; Burcu Aslan; Recep Bayraktar; Nilgun Gurbuz; Cristian Rodriguez-Aguayo; Emine Bayraktar; Merve Denizli; Vianey Gonzalez-Villasana; Cristina Ivan; Ganesh L R Lokesh; Paola Amero; Silvia Catuogno; Monika Haemmerle; Sherry Yen-Yao Wu; Rahul Mitra; David G Gorenstein; David E Volk; Vittorio de Franciscis; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Mol Ther Nucleic Acids       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.